This open-label, multicenter, Phase I, dose-escalation study will evaluate the s afety, tolerability and pharmacokinetics of GDC-0575 administered alone or in co mbination with gemcitabine in patients with refractory solid tumors or lymphoma. In Stage I, cohorts of patients will receive multiple ascending oral doses of G DC-0575 alone (Arm 1) or in combination with intravenous gemcitabine (Arm 2). In Stage II, patients will receive GDC-0575 orally in combination with intravenous gemcitabine at or below the maximum tolerated dose determined in Stage I. Antic ipated time on study treatment is until disease progression or unacceptable toxi city occurs, for a maximum of 17 cycles (approximately 1 year).
Find Clinical Trials
To find clinical trials that focus on targeted therapies, use the pulldown menus below or enter a term in the search box.
Request a Consultation
To schedule a consultation with an oncologist at Dana-Farber/Brigham and Women's Cancer Center, please call one of our experienced appointment coordinators.
